Journal of Peking University(Health Sciences) ›› 2017, Vol. 49 ›› Issue (5): 760-767. doi: 10.3969/j.issn.1671-167X.2017.05.004

• Article • Previous Articles     Next Articles

Detection of large deletions in X linked Alport syndrome using competitive multiplex fluorescence polymerase chain reaction

WANG Fang, ZHANG Yan-qin, DING Jie, YU Li-xia   

  1. Department of Pediatrics, Peking University First Hospital, Beijing 100034, China
  • Received:2017-06-22 Online:2017-10-18 Published:2017-10-18
  • Supported by:
    Supported by the National Twelfth Five-Year-Plan for Scientific and Technological Support Project (2012BAI03B02), the National Key Research and Development Program of China (2016YFC0901505), the National Natural Science Foundation of China (81070545), the Beijing Nature Science Foundation (7102148), and the Beijing Key Laboratory of Molecular Diagnosis and Study on Pediatric Genetic Diseases (Z141107004414036)

Abstract: Objective: To evaluate the ability of multiplex competitive fluorescence polymerase chain reaction in detection of large deletion and duplication genotypes of X-linked Alport syndrome. Methods: Clinical diagnosis of X-linked Alport syndrome was based on either abnormal staining of type Ⅳ collagen α5 chain in the epidermal basement membrane alone or with abnormal staining of type Ⅳ collagen α5 chain in the glomerular basement membrane and Bowman’s capsule/ultrastructural changes in the glomerular basement membrane typical of Alport syndrome. A total of 20 unrelated Chinese patients (13 males and 7 females) clinically diagnosed as X-linked Alport syndrome were included in the study. Their genotypes were unknown. Control subjects included a male patient with other renal disease and two patients who had large deletions in COL4A5 gene detected by multiplex ligation-dependent probe amplification. Genomic DNA was isolated from peripheral blood leukocytes in all the participants. Multiplex competitive fluorescence polymerase chain reaction was used to coamplify 53 exons of COL4A5 gene and four reference genes in a single reaction. When a deletion removed exon 1 of COL4A5 gene was identified, the same method was used to coamplify the first 4 exons of COL4A5 and COL4A6 genes, a promoter shared by COL4A5 and COL4A6 genes, and three reference genes in a single reaction. Any copy number loss suggested by this method was verified by electrophoresis of corresponding polymerase chain reaction amplified products or DNA sequencing to exclude possible DNA variations in the primer regions. Results: Genotypes of two positive controls identified by multiplex competitive fluorescence polymerase chain reaction were consistent with those detected by multiplex ligation-dependent probe amplification. Deletions were identified in 6 of the 20 patients, including two large deletions removing the 5' part of both COL4A5 and COL4A6 genes with the breakpoint located in the second intron of COL4A6, two large deletions removing more than 30 exons of COL4A5 gene, one large deletion removing at least 1 exon of COL4A5 gene, and one small deletion involving 13 bps. No duplication was found. Conclusion: Our results show that multiplex competitive fluorescence polymerase chain reaction is a good alternative to classical techniques for large deletion genotyping in X-linked Alport syndrome.

Key words: Alport syndrome, X-linked, Large deletion, COL4A5 gene, Multiplex competitive fluorescence polymerase chain reaction

CLC Number: 

  • R729
[1] Jais JP, Knebelmann B, Giatras I, et al. X-linked Alport syndrome: natural history in 195 families and genotype-phenotype correlations in males[J]. J Am Soc Nephrol, 2000, 11(4): 649-657.
[2] Wang F, Zhao D, Ding J, et al. Skin biopsy is a practical approach for the clinical diagnosis and molecular genetic analysis of X-linked Alport’s syndrome[J]. J Mol Diagn, 2012, 14(6): 586-593.
[3] Kashtan CE, Ding J, Gregory M, et al. Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport syndrome research collaborative[J]. Pediatr Nephrol, 2013, 28(1): 5-11.
[4] Bekheirnia MR, Reed B, Gregory MC, et al. Genotype-phenotype correlation in X-linked Alport syndrome[J]. J Am Soc Nephrol, 2010, 21(5): 876-883.
[5] Cheong HI, Park HW, Ha IS, et al. Mutational analysis of COL4A5 gene in Korean Alport syndrome[J]. Pediatr Nephrol, 2000, 14(2): 117-121.
[6] Kawai S, Nomura S, Harano T. The COL4A5 gene in Japanese Alport syndrome patients: spectrum of mutations of all exons. The Japanese Alport Network[J]. Kidney Int, 1996, 49(3): 814-822.
[7] Ceulemans S, van der Ven K, del-Favero J. Targeted screening and validation of copy number variations[J]. Methods Mol Biol, 2012, 838: 311-328.
[8] 张琰琴,赵丹,俞礼霞, 等. 多重连接依赖性探针扩增技术在X连锁Alport综合征基因诊断中的应用[J].中华医学杂志, 2012, 92(40): 2825-2829.
[9] Hertz JM, Juncker I, Marcussen N. MLPA and cDNA analysis improves COL4A5 mutation detection in X-linked Alport syndrome[J]. Clin Genet, 2008, 74(6): 522-530.
[10] Nabais Sá MJ, Fieremans N, de Brouwer APM, et al. Deletion of the 5' exons of COL4A6 is not needed for the development of diffuse leiomyomatosis in patients with Alport syndrome[J]. J Med Genet, 2013, 50(11): 745-753.
[11] Nozu K, Minamikawa S, Yamada S, et al. Characterization of contiguous gene deletions in COL4A6 and COL4A5 in Alport syndrome-diffuse leiomyomatosis[J]. J Hum Genet, 2017, 62(7): 733-735.
[12] Nabais Sá MJ, Sampaio S, Oliveira A, et al. Collagen type Ⅳ-related nephropathies in Portugal: pathogenic COL4A5 mutations and clinical characterization of 22 families[J]. Clin Genet, 2015, 88(5): 462-467.
[13] Weber S, Strasser K, Rath S, et al. Identification of 47 novel mutations in patients with Alport syndrome and thin basement membrane nephropathy[J]. Pediatr Nephrol, 2016, 31(6): 941-955.
[14] Du R, Lu C, Jiang Z, et al. Efficient typing of copy number variations in a segmental duplication-mediated rearrangement hotspot using multiplex competitive amplification[J]. J Hum Genet, 2012, 57(8): 545-551.
[15] Wang F, Ding J, Guo S, et al. Phenotypic and genotypic features of Alport syndrome in Chinese children[J]. Pediatr Nephrol, 2000, 17(12): 1013-1020.
[16] Martin P, Heiskari N, Zhou J, et al. High mutation detection rate in the COL4A5 collagen gene in suspected Alport syndrome using PCR and direct DNA sequencing[J]. J Am Soc Nephrol, 1998, 9(12): 2291-2301.
[17] Savige J, Gregory M, Gross O, et al. Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy[J]. J Am Soc Nephrol, 2013, 24(3): 364-375.
[18] Dahan K, Heidet L, Zhou J, et al. Smooth muscle tumors associated with X-linked Alport syndrome: carrier detection in females[J]. Kidney Int, 1995, 48(6): 1900-1906.
[19] Thielen BK, Barker DF, Nelson RD, et al. Deletion mapping in Alport syndrome and Alport syndrome-diffuse leiomyomatosis reveals potential mechanisms of visceral smooth muscle overgrowth[J]. Hum Mutat, 2003, 22(5): 419.
[1] . [J]. Journal of Peking University(Health Sciences), 2017, 49(5): 927-929.
[2] WANG Fang, ZHANG Yan-qin, DING Jie, YU Li-xia. Detection of large deletions in X linked Alport syndrome using competitive multiplex fluorescence polymerase chain reaction [J]. Journal of Peking University(Health Sciences), 0, (): 760-767.
[3] HAN Ye, DU Si-qian, XIAO Hui-jie, ZHOU Ying, DING Jie, DING Juan-juan, CUI Yi-min. Pharmacokinetics of once daily prolonged-release formulation of tacrolimus in child-ren with primary nephrotic syndrome#br# [J]. Journal of Peking University(Health Sciences), 0, (): 807-813.
[4] HAN Ye, DU Si-qian, XIAO Hui-jie, ZHOU Yin, DING Jie, DING Juan-juan, CUI Yi-min. Pharmacokinetics of once daily prolonged-release formulation of tacrolimus in child-ren with primary nephrotic syndrome [J]. Journal of Peking University(Health Sciences), 2017, 49(5): 807-813.
[5] . [J]. Journal of Peking University(Health Sciences), 0, (): 0-封三.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] Author. English Title Test[J]. Journal of Peking University(Health Sciences), 2010, 42(1): 1 -10 .
[2] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 188 -191 .
[3] . [J]. Journal of Peking University(Health Sciences), 2009, 41(3): 376 -379 .
[4] . [J]. Journal of Peking University(Health Sciences), 2009, 41(4): 459 -462 .
[5] . [J]. Journal of Peking University(Health Sciences), 2010, 42(1): 82 -84 .
[6] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 319 -322 .
[7] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 333 -336 .
[8] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 337 -340 .
[9] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 225 -328 .
[10] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 346 -350 .